Buttmann M - Search Results

1

Investigation of sex-specific effects of apolipoprotein E on severity of EAE and MS.

Schrewe L, Lill CM, Liu T, Salmen A, Gerdes LA, Guillot-Noel L, Akkad DA, Blaschke P, Graetz C, Hoffjan S, Kroner A, Demir S, Böhme A, Rieckmann P, ElAli A, Hagemann N, Hermann DM, Cournu-Rebeix I, Zipp F, Kümpfel T, Buttmann M, Zettl UK, Fontaine B, Bertram L, Gold R, Chan A. Schrewe L, et al. Among authors: buttmann m. J Neuroinflammation. 2015 Dec 16;12:234. doi: 10.1186/s12974-015-0429-y. J Neuroinflammation. 2015. PMID: 26669675 Free PMC article.

2

Local pain during REBIF injection is not due to acidic pH.

Buttmann M, Goebeler M, Rieckmann P. Buttmann M, et al. J Neurol Neurosurg Psychiatry. 2004 Jul;75(7):1078. doi: 10.1136/jnnp.2003.025114. J Neurol Neurosurg Psychiatry. 2004. PMID: 15201384 Free PMC article. No abstract available.

3

Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis.

Buttmann M, Merzyn C, Rieckmann P. Buttmann M, et al. J Neuroimmunol. 2004 Nov;156(1-2):195-203. doi: 10.1016/j.jneuroim.2004.07.016. J Neuroimmunol. 2004. PMID: 15465611

4

Subcutaneous interferon-beta injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction.

Buttmann M, Goebeler M, Toksoy A, Schmid S, Graf W, Berberich-Siebelt F, Rieckmann P. Buttmann M, et al. J Neuroimmunol. 2005 Nov;168(1-2):175-82. doi: 10.1016/j.jneuroim.2005.07.011. Epub 2005 Aug 26. J Neuroimmunol. 2005. PMID: 16126281 Clinical Trial.

5

Interferon-beta is a potent inducer of interferon regulatory factor-1/2-dependent IP-10/CXCL10 expression in primary human endothelial cells.

Buttmann M, Berberich-Siebelt F, Serfling E, Rieckmann P. Buttmann M, et al. J Vasc Res. 2007;44(1):51-60. doi: 10.1159/000097977. Epub 2006 Dec 13. J Vasc Res. 2007. PMID: 17167270

6

Interferon-beta1b in multiple sclerosis.

Buttmann M, Rieckmann P. Buttmann M, et al. Expert Rev Neurother. 2007 Mar;7(3):227-39. doi: 10.1586/14737175.7.3.227. Expert Rev Neurother. 2007. PMID: 17341170 Review.

7

Atorvastatin partially prevents an inflammatory barrier breakdown of cultured human brain endothelial cells at a pharmacologically relevant concentration.

Buttmann M, Lorenz A, Weishaupt A, Rieckmann P. Buttmann M, et al. J Neurochem. 2007 Aug;102(4):1001-8. doi: 10.1111/j.1471-4159.2007.04563.x. Epub 2007 Apr 17. J Neurochem. 2007. PMID: 17442054 Free article.

8

The PLPp-specific T-cell population promoted by pertussis toxin is characterized by high frequencies of IL-17-producing cells.

Hofstetter HH, Grau C, Buttmann M, Forsthuber TG, Gaupp S, Toyka KV, Gold R. Hofstetter HH, et al. Among authors: buttmann m. Cytokine. 2007 Oct;40(1):35-43. doi: 10.1016/j.cyto.2007.07.192. Epub 2007 Sep 18. Cytokine. 2007. PMID: 17881243

9

TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response.

Buttmann M, Merzyn C, Hofstetter HH, Rieckmann P. Buttmann M, et al. J Neuroimmunol. 2007 Oct;190(1-2):170-6. doi: 10.1016/j.jneuroim.2007.08.009. Epub 2007 Sep 19. J Neuroimmunol. 2007. PMID: 17884184 Clinical Trial.

10

Treating multiple sclerosis with monoclonal antibodies.

Buttmann M, Rieckmann P. Buttmann M, et al. Expert Rev Neurother. 2008 Mar;8(3):433-55. doi: 10.1586/14737175.8.3.433. Expert Rev Neurother. 2008. PMID: 18345973 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

86 results

Search Page